Curis, Inc.
(NASDAQ : CRIS)

( )
CRIS PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
BIIBBiogen, Inc.
-0.93%291.401.4%$865.23m
AMGNAmgen, Inc.
0.28%221.311.3%$495.03m
CELGCelgene Corp.
0.39%110.001.3%$448.97m
GILDGilead Sciences, Inc.
-0.50%64.321.0%$384.61m
ILMNIllumina, Inc.
0.25%295.733.5%$305.32m
VRTXVertex Pharmaceuticals, Inc.
0.97%203.861.9%$290.09m
REGNRegeneron Pharmaceuticals, Inc.
1.20%348.412.6%$262.04m
EXASEXACT Sciences Corp.
-0.77%79.9124.0%$196.13m
ALXNAlexion Pharmaceuticals, Inc.
0.39%109.442.0%$190.16m
SGENSeattle Genetics, Inc.
2.16%110.646.1%$126.52m
BMRNBioMarin Pharmaceutical, Inc.
0.73%75.884.3%$110.72m
SRPTSarepta Therapeutics, Inc.
5.46%99.9514.6%$106.88m
AAgilent Technologies, Inc.
0.26%77.051.6%$100.02m
MRTXMirati Therapeutics, Inc.
1.12%104.332.3%$89.09m
NBIXNeurocrine Biosciences, Inc.
0.50%111.405.0%$84.24m

Company Profile

Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170, and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints. The company was founded on February 14, 2000 and is headquartered in Lexington, MA.